What CVS Health Corporation's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 8 |
| Total trades | 0 | 51 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 22,637 |
| Disposed | 0 | 3,543,233 |
| Net activity | +0 | −3,520,596 |
Common stock only — 11 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Clark James David | SVP, Cont & Chief Acct Officer | Jun 26 | Withheld — tax / exercise cost · F | −454 | $90.98 | −$41.3K | 27,606 |
| Newman Brian | EVP, Chief Financial Officer | May 31 | Withheld — tax / exercise cost · F | −2,478 | $90.98 | −$225K | 3,008 |
| Compton-Phillips Amy | EVP, Chief Medical Officer | May 31 | Withheld — tax / exercise cost · F | −7,618 | $90.98 | −$693K | 9,557 |
| Aguirre Fernando | Director | May 21 | Disposition to Issuer · D | −1,563 | $93.50 | −$146K | 10,513 |
| Robbins Lawrence M | Director | May 21 | Open-market sale · S | −370,462 | $93.45 | −$34.6M | 4,824,799 |
| Aguirre Fernando | Director | May 20 | Disposition to Issuer · D | −30,437 | $93.78 | −$2.85M | 12,076 |
| Robbins Lawrence M | Director | May 20 | Open-market sale · S | −800 | $96.28 | −$77K | 5,195,261 |
| Robbins Lawrence M | Director | May 20 | Open-market sale · S | −66,881 | $95.67 | −$6.4M | 5,196,061 |
| Robbins Lawrence M | Director | May 20 | Open-market sale · S | −152,691 | $94.81 | −$14.5M | 5,262,942 |
| Robbins Lawrence M | Director | May 20 | Open-market sale · S | −797,628 | $93.48 | −$74.6M | 5,415,633 |
| Robbins Lawrence M | Director | May 19 | Open-market sale · S | −151 | $95.18 | −$14.4K | 6,213,261 |
| Robbins Lawrence M | Director | May 19 | Open-market sale · S | −1,983,387 | $94.45 | −$187M | 6,213,412 |
| Aguirre Fernando | Director | May 14 | Grant / award · A | +1,563 | $97.15 | +$152K | 42,513 |
| Brown C David Ii | Director | May 14 | Grant / award · A | +1,544 | $97.15 | +$150K | 129,316 |
| Sansone Guy P | Director | May 14 | Grant / award · A | +1,447 | $97.15 | +$141K | 15,106 |
| Norwalk Leslie V | Director | May 14 | Grant / award · A | +1,447 | $97.15 | +$141K | 7,376 |
| Kirby J Scott | Director | May 14 | Grant / award · A | +1,447 | $97.15 | +$141K | 14,434 |
| Balser Jeffrey R. | Director | May 14 | Grant / award · A | +2,058 | $97.15 | +$200K | 15,717 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | May 08 | Open-market sale · S | −69,551 | $89.58 | −$6.23M | 10,133 |
| Capozzi Heidi B | EVP and Chief People Officer | Apr 01 | Withheld — tax / exercise cost · F | −1,334 | $72.49 | −$96.7K | 13,023 |
Loading...
